Mobile

A trial to determine if rifaximin is more efficient than placebo in treating systemic inflammation and neutrophil (white blood cells) malfunction in patients with cirrhosis and chronic hepatic encepha...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-004708-20

A trial to determine if rifaximin is more efficient than placebo in treating systemic inflammation and neutrophil (white blood cells) malfunction in patients with cirrhosis and chronic hepatic encephalopathy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To test if rifaximin reduces neutrophil spontaneous oxidative burst ex vivo in patients with cirrhosis and chronic hepatic encephalopathy after 30 days.

Critère d'inclusion

  • Cirrhosis and chronic hepatic encephalopathy

Liens